

# MARKET REPORT



Carcinoembryonic Antigen (CEA) 2017-2021: US, Europe, Japan--Opportunities for Suppliers, Market Segment Forecasts and Shares, Competitive Strategies, Emerging Technologies, Instrumentation Review

**BioPortfolio**  
Life Science Healthcare and  
Pharmaceutical  
Market Research and  
Corporate Data



# Carcinoembryonic Antigen (CEA) 2017-2021: US, Europe, Japan--Opportunities for Suppliers, Market Segment Forecasts and Shares, Competitive Strategies, Emerging Technologies, Instrumentation Review

BioPortfolio has been marketing business and market research reports from selected publishers for over fifteen years. BioPortfolio offers a personal service to our customers with dedicated research managers who will work with you to source the best report for your needs. Based in the UK, BioPortfolio is well positioned to coordinate our customers' orders sourced from over 50 global report publishers.

We are pleased to present details of this report to assist your buying decision and administrative process. You will find easy-to-use *How To Buy* information on the last page of this document.

***We look forward to being of service to you.***

*If you have bulk and/or recurring requirements, please get in touch - we can liaise with publishers to obtain sample pages and negotiate discounts on your behalf.*

**Phone:** +44 (0)7887 945155 or **Email:** [bioportfolio97@gmail.com](mailto:bioportfolio97@gmail.com)

# Carcinoembryonic Antigen (CEA) 2017-2021: US, Europe, Japan--Opportunities for Suppliers, Market Segment Forecasts and Shares, Competitive Strategies, Emerging Technologies, Instrumentation Review

The cancer diagnostics market is on the verge of explosion, as the researchers approach major technological breakthroughs in tumor diagnosis and therapy, discover new specific antigens, and unlock the mystery of the genetic basis of the disease. During the next ten years, the worldwide cancer testing market is promising to be an exciting, dynamic and rapidly expanding field. Anticipated technological breakthroughs will create numerous opportunities for determining genetic predisposition, detecting specific tumors, and monitoring biological response to cancer therapy. The rise in geriatric population will further compound the growing demand for malignancy assays and the rapid market expansion worldwide.

This report presents a detailed analysis of the CEA testing market in the US, Europe (France, Germany, Italy, Spain, UK) and Japan, including clinical significance and current laboratory practice; 5- and 10-year test volume and sales forecasts by country and market segment; as well as sales and market shares for major suppliers.

The report also examines market applications of DNA probes, biochips/microarrays, monoclonal antibodies, immunoassays, IT, chromosome analysis, and other technologies; reviews features and operating characteristics of automated analyzers; profiles leading suppliers and recent market entrants developing innovative technologies and products; and identifies alternative market penetration strategies and entry barriers/risks. Contains 250 pages and 15 tables

## Additional Details

**Publisher** : Venture Planning Group (VPG)

**Reference** : VPCA21685

**Number of Pages** : 250

**Report Format** : PDF

**Publisher Information** :

**VPGMarketResearch.com**

**BioPortfolio**  
Life Science Healthcare and  
Pharmaceutical  
Market Research and  
Corporate Data

**Best Prices  
Guaranteed**

**bioportfolio.co.uk**

**BioPortfolio**  
Life Science Healthcare and Pharmaceutical  
Global Market Research and Corporate Data

# Table Of Contents for Carcinoembryonic Antigen (CEA) 2017-2021: US, Europe, Japan--Opportunities for Suppliers, Market Segment Forecasts and Shares, Competitive Strategies, Emerging Technologies, Instrumentation Review

- Request Table of Contents [reportstore@bioportfolio.com](mailto:reportstore@bioportfolio.com)

# List Of Tables in Carcinoembryonic Antigen (CEA) 2017-2021: US, Europe, Japan--Opportunities for Suppliers, Market Segment Forecasts and Shares, Competitive Strategies, Emerging Technologies, Instrumentation Review

## Company Assessments

- Abbott
- AdnaGen/Alere
- Agilent Technologies
- Applied Gene Technologies
- Arca Biopharma
- Beckman Coulter/Danaher
- Becton Dickinson
- Biomedical Diagnostics
- bioMerieux
- Bio-Rad
- CellSearch
- Cepheid
- Correlogic Systems/Vermillion
- Decode Genetics
- Diadexus
- Diagnocure
- Diasorin
- Eiken Chemical
- Elitech Group
- Enterix
- Enzo Biochem
- Epigenomics
- Fujirebio

- Guided Therapeutics
- Hologic/Gen-Probe
- Kreatech/Leica
- Kyowa Medex
- Mackay Life Sciences
- Myriad Genetics
- OncoLab
- Ortho-Clinical Diagnostics
- Panacea Pharmaceuticals
- Polartechnics
- Polymedco
- PreMD
- Qiagen
- Quest Diagnostics
- Radient Pharmaceuticals
- Roche
- Scienion
- Sequenom
- Siemens Healthcare
- Takara Bio
- Targeted Diagnostics & Therapeutics
- Thermo Fisher
- Tosoh
- Veridex
- Wako Pure Chemicals
- Wallac/PE
- Zila

# How to Buy...

Carcinoembryonic Antigen (CEA) 2017-2021: US, Europe, Japan--Opportunities for Suppliers, Market Segment Forecasts and Shares, Competitive Strategies, Emerging Technologies, Instrumentation Review

## Option 1 - Online

Go to our website and pay online with any major debit or credit card:

<https://www.bioportfolio.co.uk/product/75504>

## Option 2 - Request a Proforma Invoice

Fill in the details below, and **Scan** this page **and email** it to us at [bioportfolio97@gmail.com](mailto:bioportfolio97@gmail.com) We will send you a Proforma Invoice and deliver your report on settlement.

**Your Name:** .....

**Job Title:** .....

**Your Email:** .....

**Your Contact Phone:** .....

**Company Name:** .....

**Address:** .....

**Post/Zip Code:** .....

**Country:** .....

**P.O. Number:** .....

**Any Other Instructions:** .....

**Pricing Options:** (please tick one)

- \$3698** | Single User Price
- \$8075** | Global License Price

**Payment Options:** (please tick one)

- Online Credit Card** (we will email you the invoice with a payment link)
- Direct Wire Transfer** (we will email you the invoice with our bank details)

**Authorising Signature:** .....

## Option 3 - Phone Us on +44 (0)7887 945155

We will be delighted to give you our personal attention.